With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance broke a 50-50 deadlock in the US Senate.

The sale caps a difficult time for zilovertamab and ONCT-808 under Oncternal’s ownership. Zilovertamab was deprioritised by ...

Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.

Uruguay’s MSP has tasked a working group and a proposal has been created by the Faculty of Chemistry at the University of Uruguay.

Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission for Ziihera for biliary tract cancer.

By 2030, the cell and gene therapy market is projected to be worth £76.03bn, and logistics is essential in realising the potential.

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat ...

Vetter Pharma, has begun the construction of a new clinical manufacturing facility in Des Plaines, Illinois, US.

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some experts.